No Data
RemeGen Co., Ltd. (HKG:9995) Institutional Owners May Be Pleased With Recent Gains After 20% Loss Over the Past Year
Express News | Asco Gu｜RemeGen Announced Highly Encouraging Data From the Phase II Clinical Trial Evaluating Disitamab Vedotin Plus Immunotherapy as Perioperative Regimen for Bladder Cancer
ASCO GU|RemeGen Announced Highly Encouraging Data From the Phase II Clinical Trial Evaluating Disitamab Vedotin Plus Immunotherapy as Perioperative Regimen for Bladder Cancer
Hong Kong stock movement | REMEGEN (09995) rises over 8% again, with sales revenue in 2024 expected to exceed estimates. The company responds to the Pfizer impairment issue.
REMEGEN (09995) has risen more than 8% again, as of the time of writing, it has increased by 5.81%, priced at 15.3 Hong Kong dollars, with a trading volume of 24.852 million Hong Kong dollars.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
RemeGen Announces Executive Director Resignation
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
